Have a feature idea you'd love to see implemented?
Let us know!
NWBO Northwest Biotherapeutics Inc
Price (delayed)
$0.26
Market cap
$337.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.08
Enterprise value
$392.73M
Highlights
NWBO's net income is up by 5% since the previous quarter and by 3.2% year-on-year
Northwest Biotherapeutics's quick ratio has plunged by 58% YoY
NWBO's debt has soared by 56% YoY and by 5% QoQ
Key stats
What are the main financial stats of NWBO
Market
Valuations
Earnings
Shares outstanding
1.3B
Market cap
$337.34M
Enterprise value
$392.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
205.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
246.07
Revenue
$1.6M
Gross profit
$1.6M
Net income
-$74.47M
EBIT
-$67.95M
EBITDA
-$65.99M
Free cash flow
-$55.15M
Per share
Balance sheet
Liquidity
EPS
-$0.08
EPS diluted
-$0.08
Free cash flow per share
-$0.04
Book value per share
-$0.06
Revenue per share
$0
TBVPS
$0.02
Total assets
$29.32M
Total liabilities
$93.56M
Debt
$58.34M
Equity
-$80.12M
Working capital
-$54.37M
Debt to equity
-0.73
Current ratio
0.09
Quick ratio
0.05
Net debt/EBITDA
-0.84
Margins
Efficiency
Dividend
EBITDA margin
-4,134.6%
Gross margin
100%
Net margin
-4,666.3%
Operating margin
-3,956.8%
Return on assets
-266.6%
Return on equity
N/A
Return on invested capital
-335.4%
Return on capital employed
N/A
Return on sales
-4,257.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NWBO stock price
How has the Northwest Biotherapeutics stock price performed over time
Intraday
0.89%
1 week
-11.11%
1 month
-5.11%
1 year
-63.89%
YTD
-62.91%
QTD
-18.75%
Financial performance
How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.6M
Gross profit
$1.6M
Operating income
-$63.15M
Net income
-$74.47M
Gross margin
100%
Net margin
-4,666.3%
NWBO's operating margin is down by 41% year-on-year and by 4.7% since the previous quarter
NWBO's net margin is down by 26% YoY but it is up by 2.4% QoQ
The company's gross profit fell by 23% YoY and by 3% QoQ
Northwest Biotherapeutics's revenue has decreased by 23% YoY and by 3% QoQ
Growth
What is Northwest Biotherapeutics's growth rate over time
Valuation
What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
205.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
246.07
The EPS has contracted by 33% YoY
The equity has contracted by 23% YoY and by 4.7% from the previous quarter
The P/S is 58% below the 5-year quarterly average of 489.0 and 43% below the last 4 quarters average of 359.0
Northwest Biotherapeutics's revenue has decreased by 23% YoY and by 3% QoQ
Efficiency
How efficient is Northwest Biotherapeutics business performance
The ROS has contracted by 24% YoY but it has grown by 3.4% from the previous quarter
The ROIC has increased by 20% QoQ
The return on assets has declined by 6% year-on-year but it rose by 3.8% since the previous quarter
Dividends
What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NWBO.
Financial health
How did Northwest Biotherapeutics financials performed over time
The total assets is 69% smaller than the total liabilities
Northwest Biotherapeutics's quick ratio has plunged by 58% YoY
The current ratio has declined by 47% year-on-year
NWBO's debt is 173% higher than its equity
NWBO's debt has soared by 56% YoY and by 5% QoQ
Northwest Biotherapeutics's debt to equity has decreased by 28% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.